Biotechnology

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

Pathos AI leverages its Foundry platform to ink a $2.2B deal with Alphamab for a novel cancer drug, signaling a new era of AI-led pharma strategy.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

Gene Solutions’ academy in Malaysia signals a shift from complex genomic data to empowering clinicians with actionable insights for a new era of cancer care.

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

Human Longevity's new low-cost whole genome sequencing promises predictive health for all, but its true power lies in its AI and a vast new data asset.

Exicure is settling a $1M debt with stock, a move to preserve its dwindling cash. Can this gamble save its new focus on blood cancer therapy or just delay the inevitable?

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

Autolus Therapeutics reports a 100% year-over-year sales jump and a stunning gross margin reversal, securing a $250M credit facility to fund its next big move.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

Lipocine's appointment of M&A veteran Michael Grissinger isn't just a new face on the board; it's a clear signal of a strategic pivot towards high-stakes partnerships.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.

A new partnership aims to treat PTSD with psilocybin, revealing a broader strategy to navigate regulatory mazes and build the clinical infrastructure for a new era of medicine.

NewcelX secured a small but vital $1.4M financing at a 20% premium. It's a bold vote of confidence, but is it enough to outrun a 'going concern' warning?